Canine cIV antibody and antigen (recombinant protein)
Diagnostic anti-Canine cIV antibodies pairs and antigen for animal health (animal Dog/Canine Goodpasture syndrome, Alport syndrome, glomerular basement membrane, Liver fibrosis and cirrhosis, alcoholic liver disease, hepatitis C and fall following successful therapy. autosomal dominant hereditary angiopathy, nephropathy, aneurysms, and muscle cramps. porencephaly, schizencephaly, congenital cataract, coronary artery disease, diabetic nephropathy and renal injury.) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT
Go to Companion Animal disease testing products collection >>
Product information
Catalog No. | Description | US $ Price (per mg) |
---|---|---|
GMP-CAN-cIV-Ag01 | Canine cIV | $3090.00 |
GMP-CAN-cIV-Ab01 | Anti-Canine cIV mouse monoclonal antibody (mAb) | $3090.00 |
GMP-CAN-cIV-Ab02 | Anti-Canine cIV mouse monoclonal antibody (mAb) | $3090.00 |
GMP-CAN-cIV-Ab03 | Anti-Canine cIV human monoclonal antibody (mAb) | $3090.00 |
GMP-CAN-cIV-Ab04 | Anti-Canine cIV human monoclonal antibody (mAb) | $3090.00 |
Size: 1mg | 10mg | 100mg
Product Description
Cat No. | GMP-CAN-cIV-Ag01 |
Product Name | Canine cIV |
Target/Biomarker | Canine cIV |
Expression platform | E.coli |
Isotypes | Recombinant Antigen |
Bioactivity validation | Anti-Canine cIV antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in cIV level test of animal Dog/Canine with Goodpasture syndrome, Alport syndrome, glomerular basement membrane, Liver fibrosis and cirrhosis, alcoholic liver disease, hepatitis C and fall following successful therapy. autosomal dominant hereditary angiopathy, nephropathy, aneurysms, and muscle cramps. porencephaly, schizencephaly, congenital cataract, coronary artery disease, diabetic nephropathy and renal injury.. |
Tag | His | Reconized/Reactive Specics | Canine cIV |
Product description | Recombinant Canine cIV protein was expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. | GMP-CAN-cIV-Ab01,GMP-CAN-cIV-Ab02 |
Target/Biomarker | Canine cIV |
Product Name | Anti-Canine cIV mouse monoclonal antibody (mAb) |
Expression platform | CHO |
Isotypes | Mouse IgG |
Bioactivity validation | Recombinant Canine cIV antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Canine cIV antibodies in Canine cIV level test of animal Dog/Canine with Goodpasture syndrome, Alport syndrome, glomerular basement membrane, Liver fibrosis and cirrhosis, alcoholic liver disease, hepatitis C and fall following successful therapy. autosomal dominant hereditary angiopathy, nephropathy, aneurysms, and muscle cramps. porencephaly, schizencephaly, congenital cataract, coronary artery disease, diabetic nephropathy and renal injury.. |
Product description | Anti-Canine cIV mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Canine cIV antibodies. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. | GMP-CAN-cIV-Ab03,GMP-CAN-cIV-Ab04 |
Target/Biomarker | Canine cIV |
Product Name | Anti-Canine cIV human monoclonal antibody (mAb) |
Expression platform | CHO |
Isotypes | Human lgG1 |
Bioactivity validation | Recombinant Canine cIV antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Canine cIV antibodies in Canine cIV level test of animal Dog/Canine with Goodpasture syndrome, Alport syndrome, glomerular basement membrane, Liver fibrosis and cirrhosis, alcoholic liver disease, hepatitis C and fall following successful therapy. autosomal dominant hereditary angiopathy, nephropathy, aneurysms, and muscle cramps. porencephaly, schizencephaly, congenital cataract, coronary artery disease, diabetic nephropathy and renal injury.. |
Product description | Anti-Canine cIV mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Validation Data
Click to get more Data / Case study about the product.
Target/Biomarker Information
Canine Collagen Type IV (cIV) stands as an unassuming yet indispensable structural component in the intricate web of canine physiology. As a member of the collagen family, it shoulders the monumental responsibility of maintaining the integrity of basement membranes, a role that resonates throughout the canine body.
Structurally, cIV is a collagen protein comprising three polypeptide chains intertwined in a triple helical structure. This unique arrangement lends both strength and flexibility to cIV, making it an ideal candidate for the rigorous task of supporting basement membranes. These membranes are the unsung heroes beneath the scenes, forming a delicate yet robust interface between cells and the surrounding extracellular matrix.
Basement membranes are not merely passive barriers; they are dynamic regulators of cellular activities. cIV plays a multifaceted role within these membranes. It provides the structural framework, ensuring that basement membranes maintain their structural integrity even under mechanical stresses. Additionally, cIV interacts with various proteins and signaling molecules, contributing to the filtration properties of basement membranes and orchestrating essential cellular signaling events.
About GDU
GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.